Table of Contents

State/Territory Name: Massachusetts

State Plan Amendment (SPA)#: 24-0012

This file contains the following documents in the order listed below:

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Pages



Center for Medicaid and CHIP Services Medical Benefits and Health Programs Group

June 20, 2024

Mike Levine Assistant Secretary for MassHealth The Commonwealth of Massachusetts Executive Office of Health and Human Services Office of Medicaid One Ashburton Place, 3rd Floor Boston, MA 02108

Dear Assistant Secretary Levine:

We have reviewed Massachusetts State Plan Amendment (SPA) 24-0012 received in the Centers for Medicare and Medicaid Services (CMS) OneMAC application on March 29, 2024. This SPA updates language in the State Plan Pages regarding pharmacy coverage of drugs for the treatment of obesity.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that MA-24-0012 is approved with an effective date of January 1, 2024.

We are attaching a copy of the signed CMS-179 form, as well as the pages approved for incorporation into Texas State Plan. If you have any questions regarding this amendment, please contact Whitney Swears at Whitney.Swears@cms.hhs.gov.

Sincerely,



Deputey Director Division of Pharmacy

cc: Kaela Konefal, MassHealth Alison Kirchgasser, MassHealth Ambrosia Watts, CMS, Medicaid and CHIP Operations Group Marie DiMartino, CMS, Medicaid and CHIP Operations Group

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES 5. FEDERAL STATUTE/REGULATION CITATION 42 USC 1396r-8 7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	1. TRANSMITTAL NUMBER 2. STATE 2 4 0 1 2 M A 3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT 0 1 2 M A 4. PROPOSED EFFECTIVE DATE 1/01/2024 1/01/2024 6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a FFY_24 \$ 6,175,000 b 8,256,000 8,256,000 8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable) 0 8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION
Supplement to Attachment 3.1-A p. <mark>3a1b</mark> , 3a2 Supplement to Attachment 3.1-B pp. 3a1a- 3a1b, 3a2	Supplement to Attachment 3.1-A p. 3a1b, 3a2 Supplement to Attachment 3.1-B pp. 3a1a- 3a1b, 3a2
 SUBJECT OF AMENDMENT An amendment to update Pharmacy coverage of drugs for the treatment of obesity. 	
10. GOVERNOR'S REVIEW (Check One) GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED: Not required under 42 CFR 430.12(b)(2)(i)
11. SIGNATURE OF STATE AGENCY OFFICIAL 1 12. TYPED NAME 1 Mike Levine 1 13. TITLE Assistant Secretary for MassHealth 14. DATE SUBMITTED 3/29/2024	5. RETURN TO The Commonwealth of Massachusetts Executive Office of Health and Human Services Office of Medicaid One Ashburton Place, 3rd Floor Boston, MA 02108
FOR CMS USE ONLY	
3/29/2024	7. DATE APPROVED 6/20/2024
PLAN APPROVED - ON 18. EFFECTIVE DATE OF APPROVED MATERIAL 1 01/01/2024 1	9. SIGNATURE OF APPROVING OFFICIAL
Mickey Morgan	1. TITLE OF APPROVING OFFICIAL Deputy Director
22. REMARKS	

State authorized pen and ink updates to boxes 7 and 8 to reference page Supplement to Attachment 3.1-A page 3a1b

State Plan under Title XIX of the Social Security Act State: Massachusetts Amount, Duration and Scope of Medical And Remedial Care and Services Provided to the Categorically Needy

The Medicaid agency provides coverage for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses to all Medicaid recipients, including full benefit dual eligible beneficiaries under the Medicare Prescription Drug Benefit –Part D.

☑ The following excluded drugs are covered:

 \square (a) select agents when used for anorexia, weight loss, weight gain as outlined on the MassHealth Drug List on the state's website

 \Box (b) agents when used to promote fertility

 \square (c) agents when used for the symptomatic relief of cough and colds (covered only when dispensed to members residing in a nursing facility or an intermediate care facility for individuals with intellectual disabilities)

 \square (d) select prescription vitamins and mineral products, except prenatal vitamins and fluoride-containing products as outlined on the MassHealth Drug List on the state's website

 \square (e) select nonprescription drugs as outlined on the MassHealth Drug List on the state's website

 \Box (f) covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee

State Plan under Title XIX of the Social Security Act State: Massachusetts Amount, Duration, and Scope of Medical And Remedial Care and Services Provided to the Categorically Needy

Reserved

State Plan under Title XIX of the Social Security Act State: Massachusetts Amount, Duration and Scope of Medical And Remedial Care and Services Provided to the Medically Needy

- 2. A rebate agreement between the state and a drug manufacturer for drugs provided to the Medicaid program, submitted to CMS on March 31, 2016, and entitled, "State of Massachusetts Supplemental Rebate Agreement" has been authorized by CMS, and a value-based rebate agreement between the state and a drug manufacturer for drugs provided to the Medicaid program, submitted to CMS on March 12, 2019, and entitled, "State of Massachusetts Value-Based Supplemental Rebate Agreement" has been authorized by CMS.
- 3. Manufacturers with supplemental rebate agreements are allowed to audit utilization data. Supplemental rebates received by the state in excess of those required under the National Drug Rebate Agreement (NDRA) will be shared with the federal government on the same percentage basis as applied under the NDRA.
- 4. The unit rebate amount under the NDRA is confidential and cannot be disclosed in accordance with Section 1927(b)(3)(D) of the Social Security Act. No substantial changes will be made to the supplemental rebate agreement without CMS authorization. Supplemental rebates received pursuant to these agreements are only for the MassHealth program.
- 5. All drugs covered by the program, irrespective of a supplemental rebate agreement, will comply with the provisions of the NDRA.
- 6. The prior authorization process for covered outpatient drugs conforms to Section 1927(d)(5) of the Social Security Act. The prior authorization process provides for a turnaround response by either telephone or other telecommunications device within twenty-four hours of receipt of a prior authorization request. In emergency situations, providers may dispense at least a seventy-two hour supply of medication.
- 7. The state may agree within the terms of a supplemental rebate agreement that the covered drug(s) may or may not be subject to prior authorization, for as long as the agreement is in effect, and that the state may obtain supplemental drug rebates in either case. This may include instances in which the state imposes prior authorization on a drug or drugs for clinical purposes, instances in which the state imposes prior authorization on a drug or drugs as part of a "step-edit" approach, and instances in which the state imposes prior authorization on a drug or drugs (which may include a generic drug) when the application of the supplemental rebate on the preferred drug or drugs results in a lower net cost to the state. The state may also enter value- or outcome-based agreements.
- 8. Only drugs supplied to MassHealth members will be covered under these agreements. In addition to collecting supplemental rebates for fee-for-service claims, the state may, at its option, also collect supplemental rebates for MassHealth member utilization through MCE(s) under an agreement.
- 9. The state may continue to collect supplemental rebates under agreements that are currently in process or effect based on the form of agreement approved by CMS as part of MA-TN-012-005 until those agreements are otherwise terminated or amended to align with the CMS-approved forms referred to in paragraph 2, above.

Effective January 1, 2006, the Medicaid agency will not cover any Part D drug for full-benefit dual eligible individuals who are entitled to receive Medicare benefits under Part A or Part B.

State Plan under Title XIX of the Social Security Act State: Massachusetts Amount, Duration and Scope of Medical And Remedial Care and Services Provided to the Medically Needy

The Medicaid agency provides coverage for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses to all Medicaid recipients, including full benefit dual eligible beneficiaries under the Medicare Prescription Drug Benefit –Part D.

☑ The following excluded drugs are covered:

 \square (a) select agents when used for anorexia, weight loss, weight gain as outlined on the MassHealth Drug List on the state's website

 \Box (b) agents when used to promote fertility

 \square (c) agents when used for the symptomatic relief cough and colds (covered only when dispensed to members residing in a nursing facility or an intermediate care facility for individuals with intellectual disabilities)

 \square (d) prescription vitamins and mineral products, except prenatal vitamins and fluoride-containing products as outlined on the MassHealth Drug List on the state's website

 \blacksquare (e) select nonprescription drugs as outlined on the MassHealth Drug List on the state's website

 \Box (f) covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee

State Plan under Title XIX of the Social Security Act State: Massachusetts Amount, Duration, and Scope of Medical And Remedial Care and Services Provided to the Medically Needy

Reserved